Results 51 to 60 of about 24,922 (273)

Ethnic and Gender Disparities in Access to Deep Brain Stimulation Surgery for Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Deep brain stimulation (DBS) is an established treatment for Parkinson's disease (PD) in appropriately selected patients. DBS may be underused in certain patient populations, especially women and racialized groups. Barriers and biases to receiving DBS that could account for underuse among these groups are not well studied in Canada.
Fang Ba, Sabrina Poonja, Pouria Torabi, Kevin Yen, Bashir Daud Shah, Eric Noyes, Gail Dimapilis, Shaina Corrick, Tejas Sankar, Alex Rajput, Oury Monchi, Aleksander M. Vitali, Bukola Salami, Aakash Shetty, Janis M. Miyasaki   +14 more
wiley   +1 more source

Structural Basis of Botulinum Toxin Type F Binding to Glycosylated Human SV2A: In Silico Studies at the Periphery of a Lipid Raft

Biomolecules, 2022
Botulinum neurotoxins are the deadliest microbial neurotoxins in humans, with a lethal dose of 1 ng/kg. Incidentally, these neurotoxins are also widely used for medical and cosmetic purposes.
Fodil Azzaz, Didier Hilaire, Jacques Fantini   +2 more
doaj   +1 more source

The light chain of tetanus toxin inhibits calcium-dependent vasopressin release from permeabilized nerve endings [PDF]

, 1992
The effects of tetanus toxin and its light and heavy chain subunits on vasopressin release were investigated in digitonin-permeabilized neurosecretory nerve terminals isolated from the neural lobe of the rat pituitary gland.
Ahnert-Hilger, G., Dayanithi, G., Gratzl, Manfred, Lnk, H., Nordmann, J. J., Weller, U.   +5 more
core   +1 more source

Managing Dystonia in Partington Syndrome

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Bilateral focal hand dystonia is an almost pathognomonic sign of Partington syndrome, frequently accompanied by intellectual disability and oromotor dyspraxia. However, a few studies have focused on the treatment of this focal dystonia, making patient management uncertain.
Emilie Pichon, Aurea Alioth, Sabina Catalano Chiuvé, André Zacharia, Marta Ruiz‐Lopez, David P. Breen, Florence Zangas‐Gehri, Florent Draye, Aurore Curie, Duncan Wilson, Victor S.C. Fung, Stephen Duma, Joël Fluss, Julien F. Bally   +13 more
wiley   +1 more source

Botulinum Neurotoxin Serotypes Detected by Electrochemical Impedance Spectroscopy

Toxins, 2015
Botulinum neurotoxin is one of the deadliest biological toxins known to mankind and is able to cause the debilitating disease botulism. The rapid detection of the different serotypes of botulinum neurotoxin is essential for both diagnosis of botulism and
Alison C. Savage, Nicholas Buckley, Jennifer Halliwell, Christopher Gwenin   +3 more
doaj   +1 more source

Antipruritic Effects of Botulinum Neurotoxins [PDF]

Toxins, 2018
This review explores current evidence to demonstrate that botulinum neurotoxins (BoNTs) exert antipruritic effects. Both experimental and clinical conditions in which botulinum neurotoxins have been applied for pruritus relief will be presented and significant findings will be highlighted.
openaire   +4 more sources

Anticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Anticholinergic medications and botulinum neurotoxin injections are established treatments for dystonia, yet they carry potential side effects and practical challenges. Deep brain stimulation (DBS) is offered in case of poor response to these approaches.
Marcela A. Montiel, Alessandro Magliozzi, Wei Kang Lim, Carolina Gorodetsky, George M. Ibrahim, Alfonso Fasano   +5 more
wiley   +1 more source

Neuronal selectivity of botulinum neurotoxins

Toxicon, 2020
Botulinum neurotoxins (BoNTs) are highly potent toxins responsible for a severe disease, called botulism. They are also efficient therapeutic tools with an increasing number of indications ranging from neuromuscular dysfunction to hypersecretion syndrome, pain release, depression as well as cosmetic application.
Poulain, Bernard, Lemichez, Emmanuel, Popoff, Michel   +2 more
openaire   +3 more sources

Investigating Sleep Concerns in Cervical Dystonia

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Heterogenous, small cohorts, and co‐occurrence of pain and psychiatric burden complicate understanding of sleep in dystonia. Objective To investigate sleep concerns in cervical dystonia (CD). Methods Longitudinal data from CD‐PROBE on subjects who were toxin‐naïve, new to practice, or without injections for at least 16 weeks were ...
Abhimanyu Mahajan, David Andrés González, Cynthia Comella   +2 more
wiley   +1 more source

Clinical Relevance of Botulinum Toxin Immunogenicity [PDF]

, 2012
Botulinum toxin type A is a 150 kD protein produced by Clostridium botulinum, which exists in a complex with up to six additional proteins. The ability of botulinum toxin to inhibit acetylcholine release at the neuromuscular junction has been exploited ...
Reiner Benecke
core   +1 more source